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ABSTRACT
In Bangladesh, the National Drug Policy (NDP) 1982 was instrumental in improving the supply of essential 
drugs of quality at an affordable price, especially in the early years. However, over time, evidence showed 
that the situation deteriorated in terms of both availability of essential drugs and their rational use. The 
study examined the current status of the outcome of the NDP objectives in terms of the availability and 
rational use of drugs in the primary healthcare (PHC) facilities in Bangladesh, including affordability by 
consumers. The study covered a random sample (n=30) of rural Upazila Health Complexes (UHCs) and a 
convenient sample (n=20) of urban clinics (UCs) in the Dhaka metropolitan area. Observations on pres- 
cribing and dispensing practices were made, and exit-interviews with patients and their attendants, and 
a mini-market survey were conducted to collect data on the core drug-use indicators of the World Health 
Organization from the health facilities. The findings revealed that the availability of essential drugs for 
common illnesses was poor, varying from 6% in the UHCs to 15% in the UCs. The number of drugs dis-
pensed out of the total number of drugs prescribed was higher in the UHCs (76%) than in the UCs (44%). 
The dispensed drugs were not labelled properly, although >70% of patients/care-givers (n=1,496) reported 
to have understood the dosage schedule. The copy of the list of essential drugs was available in 55% and 
47% of the UCs and UHCs respectively, with around two-thirds of the drugs being prescribed from the list. 
Polypharmacy was higher in the UCs (46%) than in the UHCs (33%). An antibiotic was prescribed in 44% 
of encounters (n=1,496), more frequently for fever (36-40%) and common cold (26-34%) than for lower 
respiratory tract infection, including pneumonia (10-20%). The prices of key essential drugs differed widely 
by brands (500% or more), seriously compromising the affordability of the poor people. Thus, the avail-
ability and rational use of drugs and the affordability of the poor people have remained to be achieved in 
Bangladesh even 27 years after approving the much-acclaimed NDP 1982. 
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INTRODUCTION
The availability of essential drugs (medicines con-
sidered indispensable for the treatment of a disease) 
and the affordability of the common people are 
crucial for the successful functioning of any health 
system (1). It is also an important factor to prevent 
bypassing of primary healthcare (PHC) facilities by 
the common people (2). In Bangladesh, the Na-
tional Drug Policy (NDP) 1982 was instrumental in 
improving the supply of essential drugs of quality 
at an affordable price, especially in the early years 
(3). An essential drugs list (EDL), approved by the 
Government, initially identified 150 drugs with 
controlled prices. Due to the policy of buying raw 
materials from international competitive markets 
under the new policy, the prices of essential drugs 
fell sharply in the subsequent years. During 1981-
1991, the retail prices of drugs increased by 20% 
in the local market. The pharmaceutical industry 
in Bangladesh also developed rapidly following 
the implementation of the NDP 1982 (4). In 1980, 
eight multinational companies manufactured 75% 
of all products (by value) while indigenous phar-Ahmed SM and Islam QS
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maceuticals now claim a market share of more than 
75% (5).
Evidence showed that essential drugs were not of-
ten available, especially in the government health 
facilities (6). Besides, the irrational use of drugs, such 
as over-prescribing, prescribing of multiple drugs, 
use of unnecessary expensive drugs, and overuse of 
antibiotics and injections  were observed (3,7). The 
number of regulated drugs was reduced to 117 in 
1993 and again increased to 209 in 2007 to reflect 
advancement in medical sciences (8), with loosen-
ing of control in fixing the prices of non-essential 
drugs in particular and all drugs in general (9). 
The Central Medical Store of the Government dis-
tributes drugs in the public hospitals and facilities 
(10). The retail distribution presents a totally chao- 
tic situation without any regulatory mechanism. 
Although the persons dispensing drugs at the retail 
shops should have at least a short training of eight 
weeks before applying for a license, in practice, this 
is hardly followed. Of 200,000 drug stores that sell 
drugs over-the-counter in the country, only 76,000 
(38%) are approved (licensed) by the Government 
(11). 
The retail drug shops are often the first and the 
only source of healthcare outside home for the ma-
jority of patients in developing countries (12), and 
Bangladesh is no exception to this. Anybody can 
buy any drug in any quantity, including addicting 
drugs, from these shops without any prescription. 
Bangladesh is one of the few countries where there 
is high out-of-pocket (OOP) expenditure on drugs 
by households, which amounts to around 70% of 
the total OOP expenditure on health (13). Aggres-
sive marketing by the pharmaceutical companies 
in Bangladesh and the free availability of ‘prescrip-
tion only’ drugs in the unlicensed and unregulated 
retail outlets (drug shops) have worsened the situa-
tion for the rational use of drugs (14,15). 
The meagre resources of the Directorate of Drug 
Administration (the supreme regulatory authority 
in the country for drug-related affairs) have made 
it practically impossible to monitor and regulate 
these drug stores, including the large pharmaceuti-
cal sector in the country (5). As a result, many drugs 
enter the market without proper quality-assessment 
procedures, and the market is flooded with coun-
terfeit, substandard and expired drugs (16). For ex-
ample, in a testing by the drug regulating authority, 
69% of paracetamol tablets and 80% of ampicillin 
capsules, manufactured by small companies, were 
found to be below the acceptable standard, and re-
sults of an assay of drugs involving 15 brands of 
ciprofloxacin showed that 47% of collected sam-
ples contained less-than-required ingredients (17). 
In the public sector, primary-level healthcare in 
Bangladesh consists of Upazila Health Complexes 
(UHCs), with inpatient (31-bed) and basic labora-
tory facilities, and a network of sub-centres and 
community health workers. Besides the shortage 
of skilled health workforce, these centres also lack 
appropriate diagnostic facilities and medicines, 
causing a gradual decline in the use of government 
health services for the treatment of diseases from 
17% in 2000 to 13% in 2003 (18). It was observed 
that diagnoses made at the PHC level were mainly 
based on presenting complaints, history-taking, 
and clinical examinations (19). 
There has been no comprehensive study of the NDP 
in Bangladesh, which requires investigation of the 
state of the indicators relating to structure (phar-
maceutical system’s capacity to achieve the stated 
goals), process (the degree to which necessary ac-
tivities are carried out and progress over time) and 
outcome (to assess availability, affordability, quality, 
and rational use) (20). A baseline survey, conducted 
in 1992 on the use of drugs at some public-sector 
PHC facilities in rural Bangladesh, found that the 
availability and use of essential drugs were very 
low and irrational, and over-prescribing of drugs 
was common (7). Since then, no study has been 
conducted to track the changes over the years and 
guide practitioners. This study aimed at fulfilling 
this knowledge gap by investigating the availabil-
ity and rational use of drugs and the affordability of 
the common people in both rural and urban PHC 
facilities in the country. This is expected to help the 
policy-makers/practitioners understand the present 
situation and take remedial measures to reach the 
poor with ‘quality drugs at low cost’ (21). Besides, 
responsiveness of the PHC facilities and client satis-
faction were also explored.  
MATERIALS AND METHODS
Data for the study originated from a nationwide 
survey in 2009 on the rational use of essential drugs 
in the PHC facilities (22). The study was designed as 
a facility-based cross-sectional survey to collect data 
on core drug-use indicators as recommended 
by the World Health Organization (WHO) which 
could be implemented “by individuals without 
special training or access to many resources” (23). 
Sampling
Due to the time and resource constraints, the sam-
ple was limited to 30 rural UHCs and 20 UCs in 
the Dhaka City Corporation (DCC) area. The 
30 UHCs were randomly selected from the six di-
visions proportionate to size, i.e. the division with 
the largest number of UHCs provided the largest 
proportion of 30 UHCs in the sample. Again, two Ahmed SM and Islam QS Essential drugs in PHC facilities in Bangladesh
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UCs in the DCC area were selected at random from 
each of the 10 zones where the Urban PHC Project 
II provides outpatient services under a partnership 
agreement with non-government organizations 
(NGOs) selected through competitive bidding (24). 
The list of the UCs was provided by the NGOs in 
their respective working areas. 
Thirty patients attending the outpatient depart-
ments of each of the UHCs and UCs for common 
acute illnesses were enrolled in the study. They were 
selected from the total number of patients visiting 
the PHC facility in working days (consecutive) un-
til the required number of patients was obtained. 
Patients were selected by systematic random sam-
pling to avoid bias from timing of the survey (rush 
hours in the beginning or end of clinic sessions) 
or freshness or fatigue of the healthcare providers/
workers. Thus, 1,500 patients—900 in the UHCs 
and 600 in the UCs—were included in the study. 
Techniques and tools
Data were collected through observations on pres- 
cribing and dispensing practices and recording in-
formation, exit-interviews with patients and their 
attendants (for understanding dosage, responsive-
ness of the system, and satisfaction with services), 
and a mini-market survey (to elicit prices of es-
sential drugs for common illnesses). A pretested 
structured form was used for recording relevant 
data from patient-provider interactions. Another 
pretested, semi-structured questionnaire was used 
for recording information from exit-interviews of 
patients or attendants. Finally, a checklist was used 
for recording price-related information. The data-
collection instruments were prepared based on 
literature review and peer experience. These were 
then pretested by a core group of interviewers who 
received intensive training and orientation from 
the researchers conducted in an area outside the 
study areas. 
Based on the Government-approved EDL, a refer-
ence list of key essential drugs for common illness-
es (henceforth reference list), selected from reality 
check of patient registers at the UHCs, was pre-
pared (8). This reference list of 20 drugs was used 
for checking the availability of drugs in the PHC fa-
cilities and also for collecting information on prices 
through the mini-market survey. 
The survey
Trained interviewers collected data during Febru-
ary-March 2009. To understand the prescribing 
and dispensing practices, the selected UHC/UC was 
observed for two consecutive days during usual of-
fice hours (9 am-1:30 pm). The two-member survey 
team started the day by taking permission from the 
chief executive of the UHC/UC to proceed with the 
study, exploring whether there was an EDL (posted 
in public or in file) in the facility and going through 
the records of the past seven days to get an idea 
about the daily average patient-load of the facility. 
The latter information was used for deciding upon 
the interval required for taking the systematic ran-
dom sample of 30 patients. 
One interviewer placed himself at the door of the 
Doctor’s Chamber and recorded the time of entry 
and exit of the sampled patient using a stopwatch. 
The prescribing indicators were recorded from the 
prescription slip immediately after the doctor-
patient interaction was over. Another interviewer, 
posted near the dispensary, followed the sampled 
patient when s/he came out of the doctor’s cham-
ber. The time of submitting the prescription slip to 
the dispenser and the time when drugs were dis-
pensed were recorded, and the dispensing time was 
calculated. The number of drugs in the prescription 
slip, the number of drugs served by the dispenser, 
and labelling of the drugs served were recorded. 
Also, for confirming the availability of drugs, the 
reference list of drugs was read in front of the store-
keeper/dispenser, and he was asked to show the 
drugs, if available. When the drug was shown, only 
then it was recorded as available.
The same interviewer conducted an exit-interview 
with the patient or his/her attendant to elicit infor-
mation on their understanding of dosage, respon-
siveness of the system, and satisfaction with serv-
ices. The interview was conducted in a place away 
from the prescribing and dispensing site but within 
the premises of the facility. The whole process con-
tinued in this cycle until the desired number of pa-
tients was enrolled. 
Finally, a mini-market survey was conducted in the 
rural areas to find the extent of variation in market 
prices of essential drugs for common illnesses. Near 
each UHC in the sample, 10 drug stores were ran-
domly chosen, and the minimum and maximum 
prices of drugs included in the reference list were 
recorded. The prices were obtained from the sales 
people at the drug stores. The cost of a full-course of 
drugs for three common illnesses among the study 
subjects was reviewed to understand the affordabili- 
ty of the extreme poor people.
Management and analysis of data
The SPSS PC+ software (version 12) was used for ana- 
lyzing data. The summary statistics of the differ-
ent drug-use indicators were compiled to compare 
the rural and urban facilities (UHCs and UCs in the 
DCC area respectively).Ahmed SM and Islam QS
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Ethical clearance
The study proposal passed through the usual insti-
tutional review process at the Research and Evalua-
tion Division of BRAC and the ethical review board 
of the James P. Grant School of Public Health, 
BRAC University. No invasive procedure was done. 
Informed verbal consents were obtained from the 
respondents who were largely illiterate or semi-lit-
erate. The written consent form was read out and 
explained to the respondents. When the investiga-
tor was satisfied that the respondent understood it, 
including its implications, and had agreed to par-
ticipate, only then s/he was included in the survey. 
Anonymity of the respondents was maintained at 
all stages of analysis of data. 
RESULTS
In total, 900 patient-provider encounters in the 
UHCs and 600 patient-provider encounters in the 
UCs (5 patients declined to be interviewed) were 
observed. Around 27% and 40% of the patients at-
tending the UHCs and UCs respectively were aged 
≤5 years  while the proportion of patients aged ≥60 
years attending the UHCs was twice (7.2%) that of 
the UCs (3.4%). In both the types of facilities, more 
women sought care than men.
Availability of drugs 
Forty-seven percent of the UHCs and 55% of the 
UCs had a copy of the EDL (Table 1). None of the 
facilities had all the 20 drugs included in the refer-
ence list of key essential drugs for common illness-
es. However, 6% of the UHCs and 15% of the UCs 
had at least 15 of the 20 drugs in the reference list.
Rational use of drugs
The average number of drugs prescribed per visit 
(prescription) was 2.2 in the UHCs and 2.5 in 
the UCs (Table 1). The proportion of encounters 
(n=1,496) with an antibiotic prescribed was around 
44%. In more than 60% of the encounters, drugs 
were prescribed from the EDL. Polypharmacy or 
prescribing three or more drugs was quite com-
mon, especially in the UCs (46% opposed to 
33% in the UHCs) (Table 2).
Table 3 shows the extent of prescribing antibio- 
tics for selected common illnesses (exclusive) 
by the two types of facilities. A greater tendency 
was observed to prescribe antibiotics for fever (40% 
in the UHCs and 36% in the UCs) and common 
cold/cough (26% in the UHCs and 34% in the UCs) 
than for acute respiratory infection (ARI) (includ-
ing pneumonia) (10% in the UHCs and 19% in 
the UCs). Thus, the UCs performed relatively ra-
tional when prescribing antibiotics. In all the cases, 
antibiotics were prescribed without any laboratory 
investigation.
Variation in prices of drugs 
A wide variation was observed in the lowest and the 
highest market prices of the same drug. The differ-
ences were sometimes more than 500%, e.g. tablet 
iron-folic acid–1,650%, tablet mebendazole–900%, 
and benzyl benzoate lotion–817% (Table 4). 
Table 5 shows the cost of drugs for a standard regi-
men for the treatment of three common illnesses, 
such as hyperacidity (including peptic ulcer), amoe-
bic dysentery, and acute respiratory tract infection 
(including pneumonia). The cost varied from 7% 
to 8% of weekly income of the extreme poor for 
treating hyperacidity and amoebic dysentery to 
20% for treating ARI with antibiotics.
Responsiveness of the system and client 
satisfaction 
The average consulting and dispensing time was 
less in the UHCs (1-2 minutes) than in the UCs 
(2-6 minutes) (Table 6). The proportion of drugs 
dispensed out of those prescribed was much higher 
Table 1. Availability and use of drugs by study areas (%)
Characteristics
Rural UHCs 
(n=900)
UCs in DCC area 
(n=596)*
Availability
Facilities having a copy of the list of essential drugs 47.0 55.0
  Facilities where at least 15 key essential drugs from the list 
of essential drugs are available 6.0 15.0
Use
Average number of drugs per encounter 2.2 2.5
Of encounters with an antibiotic prescribed 45.0 42.7
Of drugs prescribed from the list of essential drugs  63.0 66.1
*Four patients had incomplete data and excluded from analysis; DCC=Dhaka City Corporation; 
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Table 2. Polypharmacy by study areas (%)
Prescription 
containing 
the number 
of drugs
Rural
UHCs 
(n=900)
UCs in DCC 
area (n=596)*
1 18.1 14.8
2 49.0 38.9
3 27.0 30.0
4 or more 5.9 16.2
*Four patients had incomplete data and excluded 
from analysis; DCC=Dhaka City Corporation; 
UCs=Urban clinics; UHCs=Upazila Health 
Complexes
Table 3. Antibiotics prescribed for selected 
common illnesses by study areas (%)
Illnesses 
for which 
antibiotics were 
prescribed
Rural
UHCs 
(n=405)
UCs in 
DCC area
(n=255)
Fever  40.5 36.0
Cough/
common cold 26.0 34.0
Lower 
respiratory 
tract infection 
(including 
pneumonia) 10.0 19.0
Diarrhoea  4.0 5.0
Dysentery  4.4 6.3
Body ache 7.5 7.0
Hyperacidity  2.1 1.2
Weakness  2.3 4.0
DCC=Dhaka City Corporation; UCs=Urban 
clinics; UHCs=Upazila Health Complexes
in the UHCs (76%) than in the UCs (44%). Only 
65% of the drugs dispensed in the UHCs and 43% 
in the UCs were labelled (we considered drugs as 
labelled if these could be identified by either the 
inscription on its body or the name printed in the 
original package disbursed). While instructions on 
how to take drugs were given verbally, more than 
70% of the patients or care-givers reported that 
they understood how to take the dispensed drugs. 
Table 7 presents the findings of exit-interviews 
with the respondents, i.e. patients or their attend-
ants. The mean waiting time at the UHCs (17 min-
utes) was reportedly less than that in the UCs (24 
minutes). The UHCs performed poorly in terms 
of physical examinations (42%) and maintenance 
of privacy (34%) compared to the UCs (76% and 
66%. respectively). A negligible proportion of 
the respondents from the UHCs reported paying 
unofficial charges. Overall, the level of satisfaction 
with services received from the UCs was quite high 
(95% compared to 84% for the UHCs). This was 
further corroborated by the fact that most (>90%) 
respondents mentioned they would suggest their 
friends/relatives to visit these facilities for seek-
ing care.
DISCUSSION
The study was conducted to explore the current state 
of the availability and rational use of drugs and the 
affordability of the poor people in rural and urban 
Bangladesh. We used the core indicators of WHO 
to investigate drug-use in PHC facilities (25). The 
findings of the study revealed that the availability 
of key essential drugs for common illnesses was 
poor, and an unacceptable level of polypharmacy 
has been practised in the PHC facilities, including 
misuse and overuse of antibiotics. Generic prescrib-
ing was totally non-existent, and the affordability 
of the common people was severely compromised 
due to the variation in the retail prices of key essen-
tial drugs as much as 500% or more. The implica-
tions of these findings are discussed in the context 
of ‘reaching the poor with quality drugs at low cost’ 
as envisioned in the NDP 1982.
The EDL includes a core list of minimum drugs 
that satisfy the healthcare needs of the majority of 
the population in a particular country and should 
be available all times in adequate quantity and 
prescribed in appropriate dosage (20). While com-
paring with the previous survey of UHCs (7), an 
improvement was observed in relation to the avail-
ability of a copy of the EDL but deterioration was 
observed in the availability of key essential drugs 
for common illnesses. This is also consistent with 
the fact that lack of medicines was the most com-
mon complaint for which progressive deterioration 
in the use of government health services was ob-
served during 1999-2003 (18).
Around two-thirds of the drugs were prescribed 
from the EDL. The drugs prescribed from the EDL 
in the UHCs recorded a substantial fall compared to 
what was found by Guyon et al. (from 85% to 63% 
in this study) (7). A similar level of prescription from 
the EDL was reported from Serbia (25) but a higher 
level was reported from India (26), Laos (27), and 
Tanzania (28). Thus, Bangladesh is lagging behind 
other low-income countries in this aspect. None of 
the drugs dispensed from any of the facilities was 
labelled properly (i.e. generic name of drug, dosage, 
etc.) as also observed in India (26), Tanzania (28), 
and Cambodia (29). However, the self-reported 
knowledge of patients or attendants on correct dos-
age observed in the UHCs (around 65%) was com-
parable (26,27) or even better than that reported in 
other studies (28,29).
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Polypharmacy or prescribing three or more drugs 
increases the risk of drug interactions, dispensing 
errors, and proper comprehension of the correct 
dosage (25). In this study, we found polypharmacy 
on the rise: compared to 5% polypharmacy report-
ed earlier in UHCs (7), we found this to be 33%, 
which should raise our concern. The proportion of 
polypharmacy was even higher (46%) in our UCs 
compared to that found in Indonesia (30). The av-
erage number of drugs prescribed per encounter in 
the UHCs (2.2) was higher than that observed in 
the earlier study (1.4). Such a higher number was 
also observed in studies in Serbia (25), India (26), 
Laos (27), and Tanzania (28). 
The proportion of encounters/prescriptions with 
an antibiotic prescribed was around 44% when 
UHCs and UCs taken together; it was high-
er in the UHCs (45%) compared to an earlier 
study in Bangladesh (25%) (7) and other studies 
(27,30). Of more concern is the fact that antibio- 
tics were much less frequently used for lower respi-
ratory tract infections and pneumonia where it is 
warranted. Such an irrational use of antibiotics is 
responsible for the development of antibiotic resist-
ance (31).
The anarchy prevailing in the drug market is well-
amplified by the wide variation in the prices of 
drugs by brands; sometimes the difference ranged 
from 500% to more than 1,000%. A similar situ-
ation was also observed in other low- and middle-
income countries (32). This seriously compromises 
the affordability of the poor people for quality 
drugs. Lower-priced drugs are mainly marketed by 
small local companies against whom complaints of 
producing low-quality drugs are common (33). As 
observed in the present study, the cost of a stand-
Table 4. Lowest and highest prices of selected essential drugs for common illnesses 
Reference drugs from the list prepared 
by the study team (unit)
Current market price (Tk*) % of 
difference Lowest  Highest 
1 ORS (1 pack)  2.00 5.00 150
2 Tablet co-trimoxazole (1 tablet) 0.80 2.50 213
3 Syrup co-trimoxazole (60 mL) 11.00 26.65 142
4 Syrup amoxicillin (100 mL) 20.00 60.00 200
5 Tablet ciprocine (1 tablet) 4.00 16.00 300
6 Syrup ciprocine (100 mL) 37.00 95.00 157
7 Tablet aluminium hydroxide + magnesium 
hydroxide (1 tablet)  0.50 1.50 200
8 Tablet aluminum hydroxide + magnesium 
hydroxide (1 tablet)   11.00 65.00 491
9 Tablet ranitidine 150 mg (1 tablet) 1.00 4.00 300
10 Tablet paracetamol (500 mg) (1 tablet) 0.50 2.00 300
11 Tablet aspirin (300 mg) (1 tablet) 0.50 2.00 300
12 Tablet IFA (1 tablet) 0.20 3.50 1650
13 Tablet B complex per bottle (45 tablets) 12.00 90.00 650
14 Tablet ascorbic acid (1 tablet) 0.50 2.00 300
15 Tablet mebendazole (1 tablet) 0.50 5.00 900
16 Tablet albendazole (1 tablet) 1.00 6.00 500
17 Tablet atenolol 50 mg (1 tablet) 0.70 4.00 330
18 Tablet prednisolone 5 mg (1 tablet) 0.50 1.50 200
19 Benzyl benzoate lotion 25% (1 ph) 6.00 55.00 817
20 Chloramphenicol eye drop 10 mL (1 bottle) 10.00 35.00 250
21 Chloramphenicol eye ointment (1 tube) 7.00 45.00 543
22 Xylometazoline nasal drop 15 mL (1 bottle) 6.00 35.00 483
23 Miconazole ointment 10 g (1 tube) 13.00 90.00 592
24 Tablet metronidazole 400 mg (1 tablet) 0.50 3.00 500
*Exchange rate at the time  of survey: US$ 1=Tk 69; IFA=Iron-folic acid; ORS=Oral rehydration solutionAhmed SM and Islam QS Essential drugs in PHC facilities in Bangladesh
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Table 5. Cost of standard minimum dose of drugs commonly prescribed by upazila doctors for selected 
common illnesses as a percentage of weekly income of the extreme poor (@ US$ 1 a day)*
Illness/disease Drug
Standard minimum 
dose commonly 
prescribed  by 
upazila doctors
Cost (Tk)   
(US$ 1=Tk 69)*
Cost as 
percentage 
of weekly 
income**
Hyperacidity, 
including peptic 
ulcer
Aluminium 
hydroxide+ 
magnesium 
hydroxide 
suspension 
15-30 mL everyday 
up to 6 weeks or 
until pain subsides
55 (per week) 13.28
Tab ranitidine 
150 mg
2 tablets daily for 4 
weeks
28 (per week) 6.76
Amoebic dysentery Tablet 
metronidazole 
400 mg
800 mg 3 times 
daily for 5 days 
(adult)
30 7.24
Syrup 
metronidazole
15 mL daily for 5 
days (child)
45 10.86
Lower respiratory tract 
infection, including 
pneumonia
Capsule 
amoxicillin
500 mg 3 times 
daily for 7 days
105 25.36
Syrup 
amoxicillin
10 mL 3 times daily 
for 7 days (children 
aged >2 years)
90 21.73
Syrup co-
trimoxazole
10 mL daily for 7 
days (children aged 
up to 5 years)
40 9.66
*Exchange rate at the time of survey; **Assuming work for 6 days a week
Table 6. Patient-care indicators by study areas
Indicator
Rural
 UHCs (n=900)
UCs in DCC area 
(n=596)*
Average consultation time (minutes) 1.8 5.8
Average dispensing time (minutes) 0.9 2.1
% of drugs actually dispensed 76.3 44.0
% of drugs adequately labelled 65.4 43.0
% of patient’s knowledge of correct dosage 
(self-reported) 73.0 76.0
*Four patients had incomplete data and excluded from analysis; DCC=Dhaka City Corporation; 
UCs=Urban clinics; UHCs=Upazila Health Complexes
ard regimen of treatment for a common illness 
was quite substantial for the extreme poor when 
compared with their income of one dollar a day. 
The poor regulatory and supervisory mechanism 
in the country contributes to this price-hike (9,21). 
This high cost of medicines and the low availabil-
ity of essential medicines due to the failure of the 
government regulatory mechanism were also ob-
served in middle-income countries, such as Ma-
laysia, with the relatively-stable and effective 
public-health system (34). Evidence shows that 
it is possible to improve the availability of essen-
tial drugs, including the affordability of consumers 
by market regulation throughout the supply-chain 
from the manufacturer to the patient and through 
the competitive purchasing process of raw materi-
als (35,36). As OOP expenditure for drugs is high 
in Bangladesh and all prescribed drugs are not 
always available at facilities, the poor regulation 
contributes  to  the  catastrophic  health  expendi-
ture for poor households (18,37).  
Responsiveness or responding to people’s expecta-
tions is one of the main objectives of the health 
system (38). In the core indicators of WHO for the 
rational use of drugs, the quality of care provided Ahmed SM and Islam QS
JHPN 106
Essential drugs in PHC facilities in Bangladesh
Table 7. Findings from exit-interviews on satisfaction with services received, by sex and study areas (%)
Characteristics of services 
received
Rural UHCs UCs in DCC area
Male
(n=379)
Female
(n=521)
All
(n=900)
Male
(n=189)
Female
(n=406)
All
(n=595)*
Waiting time at facilities (mean) 14.6 18.6 16.9 23.9 24.6 24.5
Doctors listened to problems  
attentively 94.0 94.0 94.0 98.0 99.0 99.0
Physical examinations done 
by doctors 44.0 40.0 42.0 76.0 76.0 76.0
Privacy was maintained by 
doctors 35.0 33.0 34.0 62.0 68.0 66.0
All prescribed medicines were 
given from the facility 65.0 73.0 70.0 29.0 37.0 34.0
Paid unofficial charge(s) 4.0 3.0 3.0 0.0 0.0 0.0
Satisfied with services 84.0 83.0 84.0 95.0 95.0 95.0
Will suggest to relatives/friends to 
visit this facility  93.0 93.0 93.0 99.5 98.0 99.0
*Five patients refused to participate; DCC=Dhaka City Corporation; UCs=Urban clinics; 
UHCs=Upazila Health Complexes
is measured by the time taken in consultation and 
dispensing (including time for instruction on how 
to take drugs). The average consulting and dispens-
ing time in the UHCs increased from what was 
found earlier (15) but lagged behind other coun-
tries, e.g. Serbia (25). Such a short time is neither 
adequate for history-taking and examination of 
patients nor giving them sufficient information 
on the dosage of drugs and necessity for compli-
ance. Also, lack of proper physical examinations of 
patients and maintenance of privacy question the 
responsiveness of the system.
This study is an improvement from the earlier 
study on the use of drugs at the UHCs (7). It cov-
ered a larger, representative sample of upazilas in 
the country and additionally included an urban 
sample from the DCC area. The sample-size was 
adequate as per recommendations of the Interna-
tional Network for the Rational Use of Drugs and 
WHO to compare facilities (23). On the other hand, 
due to practical reasons, we had to use proxy indi-
cators for certain components, such as ‘labelling’, 
and we did not explore whether drugs prescribed 
followed the standard guidelines as most recorded 
diagnoses were non-specific. 
Conclusions
Except the early years in the eighties, the NDP 1982 
could not ensure the availability and rational use of 
drugs and the affordability of the common people 
over the long term in Bangladesh as exemplified 
in the present study. The situation has rather de-
teriorated in the past 15 years, especially in rural 
areas. Concerted efforts are needed to motivate and 
train those in the medical profession and allied 
health professions (e.g. nurses, paramedics, in-
formal allopathic practitioners, drug dispensers, 
and manufacturers) about the benefits of generic 
prescribing (which can lead to cost savings) and 
prescribing from the national EDL, especially for 
the poor. Polypharmacy and overuse/misuse of 
drugs, especially antibiotics, should be discouraged 
to avoid drug resistance and its consequences. Be-
sides, strengthening the regulatory capacity of the 
Directorate of Drug Administration for quality and 
price will be needed. Finally, the need of essential 
laboratory services at the PHC-level facilities for the 
proper diagnosis of illnesses which require antibi-
otics (e.g. childhood pneumonia) and the rational 
use of drugs cannot be overemphasized (39). 
ACKNOWLEDGEMENTS
The study was funded by the Swedish International 
Development Agency through the Bangladesh 
Health Watch, a civil society initiative “to regularly 
and systematically measure and monitor the coun-
try’s progress and performance in health.”
The authors gratefully acknowledge the time and 
experiences shared by the staff of the participat-
ing UHCs and UCs in the study. Thanks are due 
to Dr. Abbas Bhuiya of icddr,b and Dr. Mushtaque 
R. Choudhury of the Rockefeller Foundation for 
their encouragement and guidance in conducting 
the study, and Prof. Md. Sayedur Rahman of the 
Bangabandhu Sheikh Mujib Medical University for 
helping in designing the study. Special thanks are 
due to Mr. Farid Ahmed of the Research and Evalu-
ation Division, BRAC, for helping with data and 
field management and Mr. Hasan Shareef Ahmed 
for editing the manuscript.Ahmed SM and Islam QS Essential drugs in PHC facilities in Bangladesh
Volume 30 | Number 1 | March 2012 107
REFERENCES
1.  Chaudhury RR, Parameswar R, Gupta U, Sharma S, 
Tekur U, Bapna JS. Quality medicines for the poor: 
experiences of the Delhi programme on rational use 
of drugs. Health Policy Plan 2005;20:124-36.
2.  Swedish International Development Agency. Improv-
ing access to essential pharmaceuticals. Stockholm: 
Department for Democracy and Social Development, 
Swedish International Development Agency, 2001. 
12 p.
3.  Islam N. Bangladesh national drug policy: an exam-
ple for the Third World? Trop Doct 1999;29:78-80.
4.  Reich MA. Bangladesh pharmaceutical policy and 
politics. Health Policy Plan 1994;9:130-43.
5.  Begum R. Pharmaceutical industries: potentials and 
possibilities. NDC J 2007;6:73-89.
6.  Omer K, Cockcroft A. Bangladesh hospital improve-
ment  initiative:  follow-up  community  based  user’s 
survey: final report. London: CIET Europe, 2003. 51 p. 
(http://www.ciet.org/_documents/2006227135026.
pdf, accessed on 1 July 2011).
7.  Guyon AB, Barman A, Ahmed JU, Ahmed AU, Alam 
MS. A baseline survey on use of drugs at the primary 
health care level in Bangladesh. Bull World Health Or-
gan 1994;72:265-71.
8.  Bangladesh. Ministry of Health and Family Welfare. 
List of essential drugs. Bangladesh Gazette Notifica-
tion No. janashasthya-1/oushod-13/2006/187 dated 
22 May 2008. Dhaka: Public Health-1 Branch, Minis-
try of Health and Family Welfare, Government of 
Bangladesh, 2008. (http://www.searo.who.int/Link-
Files/Essential_Drugs_and_Medicines_BAN1.pdf, acc- 
essed on 4 July 2011). 
9.  Roy P. Essential drugs turn costlier: 20 top pharma-
ceutical companies to set minimum selling price. 
Daily Star 2005 Oct 13;5:1. 
10. World Health Organization. Drug control and distri-
bution in Bangladesh: a case study. Geneva: World 
Health Organization, 1985. 8 p. (WHO/CONRAD/
WP/2.4.1).
11. World Bank. Public and private sector approaches to 
improving pharmaceutical quality in Bangladesh. 
Dhaka: Human Development Unit, South Asia Re-
gion, World Bank, 2008. 48 p. (Bangladesh develop-
ment series no. 23).
12. Kamat VR, Nichter M. Pharmacies, self-medication 
and pharmaceutical marketing in Bombay, India. Soc 
Sci Med 1998;47:779-94.
13. Bangladesh. Ministry of Health and Family Welfare. 
Bangladesh national health accounts, 1999-2001. 
Dhaka: Health Economics Unit, Ministry of Health 
and Family Welfare, Government of Bangladesh, 
2003. 189 p.
14. Islam MS, Farah SS. Misleading promotion of drugs 
in Bangladesh: evidence from drug promotional 
brochures distributed to general practitioners by 
the pharmaceutical companies. J Public Health (Oxf) 
2007;29:212-3.
15. Babu MM. Factors contributing to the purchase of 
over the counter (OTC) drugs in Bangladesh: an em-
pirical study. Internet J Third World Med 2008;6:20. 
(http://www.ispub.com/journal/the-internet-jour-
nal-of-third-world-medicine/volume-6-number-2/
factors-contributing-to-the-purchase-of-over-the-
counter-otc-drugs-in-bangladesh-an-empirical-study.
html, accessed on 3 July 2011).
16. Fake drugs flood Bangladesh. Pharma industry: 
South Asia. A Chronicle Pharmabiz Special. Thurs-
day, 28 October 2004. (http://saffron.pharmabiz.
com/article/detnews.asp?articleid=24467&sectio
nid=50, accessed on 4 July 2011). 
17. United States Pharmacopeia. A review of drug qual-
ity in Asia with focus on anti-infectives. Rockville, 
MD: United States Pharmacopeia, 2004. 51 p. (http://
www.usp.org/pdf/EN/dqi/aneReview.pdf, accessed 
on 2 February 2011).
18. Cockcroft A, Andersson N, Milne D, Hossain MZ, Ka-
rim E. What did the public think of the health serv-
ices reform in Bangladesh? Three national communi-
ty-based surveys 1999–2003. Health Res Policy Systems 
2007;5:1. (http://www.health-policy-systems.
com/content/5/1/1, accessed on 2 February 2011).
19. Essential laboratory services for NGO primary health 
care clinics in Bangladesh. Health Sci Bull 2007;5:4-9. 
20. Brudon P, Rainhorn JD, Reich MR. Indicators for 
monitoring national drug policies: a practical manu-
al. 2nd ed. Geneva: World Health Organization, 
1999:17-29.
21. Islam MS. A review on the policy and practice of 
therapeutic drug uses in Bangladesh. Calicut Med J 
2006;4:e2.
22. Ahmed SM, Islam QS. Rational use of essential drugs 
in the public and private sector PHC facilities in 
Bangladesh: current situation and future directions. 
Dhaka: James P. Grant School of Public Health, BRAC 
University, 2009. 37 p. (Bangladesh Health Watch 
2008 background paper no. 1).
23. World Health Organization. How to investigate drug 
use in health facilities: selected drug use indicators. 
Geneva: World Health Organization, 1993. 92 p. 
(WHO/DAP/93.1) (EDM research series no. 007).
24. Bangladesh. Ministry of Local Government, Rural 
Development & Co-operatives. Second Urban Prima-
ry Health Care Project: quarterly performance report, 
Jan.- Mar. 2009. Dhaka: Project Management Unit, 
Ministry of Local Government, Rural Development 
& Co-operatives, Government of Bangladesh, 2009. 
44 p. Ahmed SM and Islam QS
JHPN 108
Essential drugs in PHC facilities in Bangladesh
25. Jankovic SM, Vasic LM, Maksimovic MR, Cupurdija 
VB, Kostic IR, Kovacevic ZN. An analysis of drug use 
indicators in primary care health facilities operating 
in the city of Kragujevac. General practice on-line 
1999.  (http://priory.com/fam/Kosovo.htm,  accessed 
on 4 July 2011).
26. Karande S, Sankhe P, Kulkarni M. Patterns of prescrip-
tion and drug dispensing. Indian J Pediatr 2005;72:117-
21.
27. Keohavong B, Syhakhang L, Sengaloundeth S, Nishi- 
mura A, Ito K. Rational use of drugs: prescribing and 
dispensing practice at public health facilities in Lao 
PDR. Pharmacoepidemiol Drug Saf 2006;5:344-7.
28. Nsimba SE. Assessing prescribing and patient care 
indicators for children under five years old with ma-
laria and other disease conditions in public primary 
health care facilities. Southeast Asian J Trop Med Public 
Health 2006;37:206-14. 
29. Chareonkul C, Khun VL, Boonshuyar C. Rational 
drug use in Cambodia: study of three pilot health 
centers in Kampong Thom province. Southeast Asian 
J Trop Med Public Health 2002;33:418-24.
30. Arustiyono. Promoting rational use of drugs at the 
community health centers in Indonesia. Boston: De-
partment of International Health, School of Public 
Health, Boston University, 1999. (MPH dissertation). 
(http://archives.who.int/prduc2004/Resource_Mats/
Asia_papers/PROMOTING%20RATIONAL%20
USE%20OF%20DRUGS%20IN%20INDONESIA.
htm, accessed on 4 July 2011). 
31. Larsson M. Antibiotic use and resistance: assessing 
and improving utilization and provision of antibiot-
ics and other drugs in Vietnam. Stockholm: Karolin-
ska University Press, 2003. 92 p. (PhD thesis). (http://
publications.ki.se/jspui/bitstream/10616/38492/1/
thesis.pdf, accessed on 4 July 2011). 
32. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Jr., 
Khatib O et al. The availability and affordability of se-
lected essential medicines for chronic diseases in six 
low- and middle-income countries. Bull World Health 
Organ 2007;85:279-88.
33. Chowdhury N, Kabir ER. Per pill price differences 
across therapeutic categories: a study of the essential 
drugs brands marketed by multinational and local 
pharmaceutical companies in Bangladesh. Afr J Mar-
ket Manage  2009;1:220-6.
34. Babar ZUD, Ibrahim MI, Singh H, Bukahri NI, Creese 
A. Evaluating drugs prices, availability, affordability, 
and price components: implications for access to 
drugs in Malaysia. PLoS Med 2007;4:e82.
35. Maïga D, Williams-Jones B. Assessment of the impact 
of market regulation in Mali on the price of essen-
tial medicines provided through the private sector. 
Health Policy 2010;97:130-5.
36. World Health Organization. The world medicines 
situation. Geneva: World Health Organization, 2004: 
61-74. (WHO/EDM/PAR/2004.5).
37. van Doorslaer E, O’Donnell O, Rannan-Eliya RP, 
Somanathan A, Adhikari SR, Garg CC et al. Catas- 
trophic payments for health care in Asia. Health Econ 
2007;16:1159-84.
38. World Health Organization. The world health report 
2000. Health systems: improving performance. Ge-
neva: World Health Organization, 2000. 215 p.
39. World Health Organization. Health laboratory servi- 
ces in support of primary healthcare in South-East 
Asia. 2nd ed. Geneva: World Health Organization, 
2007. 235 p. (WHO regional publications, SEARO se-
ries no. 24).